FDA Section 361 Compliance Checklist for HCT/Ps

An FDA Section 361 compliance checklist for human cellular and tissue products (HCT/Ps) verifies that a biologic meets all four criteria under 21 CFR 1271.10(a): minimal manipulation, homologous use, no combination with other active agents, and no systemic or metabolic dependency—unless used autologously or in first- or second-degree blood relatives. For medical practice managers, documenting these criteria alongside tissue bank registration, donor eligibility records, and adverse event tracking protocols is essential to mitigate regulatory risk during procurement. If a product fails any single criterion, it is regulated as a drug, device, or biological product under Section 351, requiring an Investigational New Drug (IND) application or Biologics License Application (BLA).

Understanding the Regulatory Divide: Section 361 vs. Section 351

In regenerative medicine, the operational and legal risk profile of your clinic depends heavily on how your biologics are classified by the Food and Drug Administration (FDA). Human cells, tissues, and cellular and tissue-based products (HCT/Ps) are regulated under Title 21 of the Code of Federal Regulations (CFR) Part 1271.

The FDA separates these products into two distinct pathways:

1. PHS Act Section 361 Products: These are HCT/Ps that meet all strict criteria listed in 21 CFR 1271.10(a). They are regulated solely to prevent the introduction, transmission, and spread of communicable diseases. They do not require premarket approval (such as a BLA or PMA) to be commercially distributed and used in clinical practice.
2. PHS Act Section 351 Products: Any HCT/P that does not meet all the criteria of Section 361 is regulated as a biological product, drug, or medical device. These products cannot be legally marketed or administered to patients without an approved BLA or an active IND application.

For practice administrators, the challenge is that certain manufacturers or third-party brokers may market perinatal tissues, amniotic allografts, or extracellular vesicles as "361-compliant" when their processing methods or promotional claims actually push them into the Section 351 category. Implementing a standardized procurement audit protects the practice, its medical license holders, and its patients.

The Core FDA Section 361 Compliance Checklist for Human Cellular and Tissue Products

When onboarding a new vendor or auditing your current inventory of allografts, use this operational checklist to evaluate regulatory alignment.

1. The Four Statutory Criteria (21 CFR 1271.10(a))

To qualify as a Section 361 HCT/P, the product must satisfy all four of the following conditions:

• Minimal Manipulation: For structural tissue (such as amniotic membrane, bone, or Wharton's Jelly), processing must not alter the original relevant characteristics of the tissue relating to its utility for reconstruction, repair, or replacement. For cells or nonstructural tissues (such as cord blood), processing must not alter the relevant biological characteristics of the cells.
• Homologous Use Only: The product must perform the same basic function or functions in the recipient as in the donor. Crucially, the FDA evaluates homologous use based on the manufacturer's labeling, advertising, and objective intent. If a vendor markets a structural cushioning tissue for systemic anti-aging or metabolic disease reversal, it fails the homologous use requirement.
• No Combination with Other Articles: The HCT/P cannot be combined with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent—provided that the addition raises no new clinical safety concerns.
• No Systemic Effect or Metabolic Dependency: The HCT/P must either (a) not have a systemic effect and not depend upon the metabolic activity of living cells for its primary function, OR (b) if it does have a systemic effect or depends on living cells, it must be for autologous use, allogeneic use in a first- or second-degree blood relative, or reproductive use.

2. Vendor and Tissue Bank Documentation

Before signing a purchasing agreement, the practice manager should request and archive the following compliance documents:

• Active FDA Establishment Registration (Form FDA 3356): Verify the tissue processor in the FDA’s electronic Human Cell and Tissue Establishment Registration (eHCTER) public database. Note that registration is self-reported and does not equal FDA approval, but lack of registration is an immediate disqualifier.
• Current Good Tissue Practice (cGTP) Compliance: Request the vendor's most recent quality assurance audit summaries demonstrating compliance with 21 CFR Part 1271 Subpart D.
• FDA Inspection History: Ask the vendor to disclose if the processing laboratory has received an FDA Form 483 (Inspectional Observations), an Untitled Letter, or a Warning Letter within the past five years, along with their corrective action responses.
• Accreditation Credentials: While voluntary, accreditation by the American Association of Tissue Banks (AATB) indicates adherence to rigorous industry standards for tissue recovery and processing.
• Distributor Licensing: Ensure your distributor holds appropriate state-level medical device or wholesale distribution licenses (for example, Dallas Regenerative Solutions operates under Texas medical device distributor license #1002308).

3. Lot-Level and Shipment Verification

Every individual shipment arriving at your clinic should be checked by the receiving clinical staff before being logged into active inventory:

• Donor Eligibility Determination: Each tissue unit must be accompanied by documentation confirming the donor was screened and tested for relevant communicable disease agents and diseases (RCDADs), including HIV, Hepatitis B and C, and syphilis, in accordance with 21 CFR 1271 Subpart C.
• Certificate of Analysis (CoA) / Package Insert: Verify that the package insert clearly states the tissue's regulatory classification, processing methodology, storage requirements, and instructions for preparation.
• Distinct Identification Code: Per 21 CFR 1271.290, every HCT/P must be assigned a unique alphanumeric code that relates the product back to the donor and to all records pertaining to the tissue—without revealing the donor's identity.
• Cold-Chain Integrity: If the product requires cryogenic or ultra-low temperature storage, document the condition of the dry ice or liquid nitrogen dry shipper upon arrival and log the transfer into your clinic's monitored freezer.

Clinical Considerations for Treating Physicians

While practice managers manage procurement and documentation, treating clinicians—such as orthopedic doctors and pain management doctors—carry the responsibility for compliant clinical application and patient communication.

From a clinical perspective, the most common regulatory pitfall involves the intersection of minimal manipulation and homologous use during patient consultations and marketing:

• Structural vs. Cellular Claims: Under FDA guidance, birth tissues like amniotic membrane and Wharton's Jelly are considered structural tissues. Their basic functions in the donor are to serve as a protective barrier, cover, or cushioning structural support. If a processing lab grinds, micronizes, or enzymatically digests the tissue in a way that alters its physical integrity beyond acting as a structural scaffold, the FDA may view it as more than minimally manipulated. Furthermore, clinicians must ensure their chart notes and patient consent forms reflect structural support or barrier applications rather than systemic cellular regeneration.
• Autologous Alternatives: When clinical protocols call for cellular signaling without the regulatory complexities of allogeneic tissue banking, physicians frequently utilize autologous point-of-care procedures, such as Platelet-Rich Plasma (PRP), or integrate non-biologic regenerative modalities. Combining compliant regenerative devices—such as Extracorporeal Shockwave Therapy (ECSWT) or High-Power Laser Therapy (HPLT)—gives clinicians versatile options to support tissue recovery while maintaining a conservative regulatory footprint.
• Marketing Alignment: The Federal Trade Commission (FTC) and FDA actively monitor clinic websites, social media, and seminar materials. Physicians must review all external marketing to ensure the practice is not making unsubstantiated disease-treatment claims for unapproved HCT/Ps.

Evaluating Vendor Red Flags in the Biologics Supply Chain

As a practice administrator, part of your role is protecting the clinic from aggressive sales tactics that misrepresent FDA policy. Be cautious if a prospective supplier exhibits any of the following behaviors:

• Claiming a Product is "FDA Approved" under Section 361: Section 361 products are never FDA approved. They are self-designated by the manufacturer and regulated under cGTP rules. Only Section 351 products with a Biologics License Application are FDA approved.
• Using TRG Letters as a Blanket Endorsement: The FDA Tissue Reference Group (TRG) provides informal, non-binding feedback to manufacturers regarding whether a specific product appears to meet 361 criteria based on submitted descriptions. A TRG letter is not a formal regulatory clearance, and vendors should not present it as an official license to market for off-label indications.
• Providing "Coaching" on How to Evade Scrutiny: If a sales representative encourages your clinic to use specific code words on your website while verbally promising systemic therapeutic outcomes to patients, terminate the vendor evaluation immediately.

What This Means for Your Practice

Building a compliant regenerative service line does not require legal guesswork, provided your administrative team establishes strict standard operating procedures (SOPs) before purchasing inventory. To put this checklist into action this quarter, take the following steps:

1. Create a Central Compliance Binder: Maintain a physical and digital binder containing the FDA Form 3356, AATB certificates, and sample package inserts for every biologic product stocked in your facility.
2. Standardize Your Tissue Log: Ensure your medical assistants record the unique donor identification code, lot number, expiration date, and recipient patient ID for every graft administered, maintaining these records for at least 10 years as aligned with federal tracking standards.
3. Audit Your Marketing Materials: Conduct a quarterly review of your clinic’s brochures, consent forms, and website copy to verify that language surrounding HCT/Ps remains strictly educational and aligned with homologous structural functions.
4. Partner with Vetted Distributors: Consolidate your purchasing through established, licensed distributors that prioritize regulatory transparency and supply chain traceability across both biologics and medical supplies.

If your practice is auditing its current biologic vendors or looking to expand its regenerative workflows with properly vetted tissue products and capital equipment, our team is available to assist. Contact Dallas Regenerative Solutions to schedule a procurement and operational consultation for your clinic.